Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Papillary thyroid carcinomas are associated with nonoverlapping activating mutations of RET, NTRK, RAS and BRAF, which altogether are present in approximately 70% of cases. We postulated that compounds that inhibit a distal effector in the mitogen-activated protein kinase (MAPK) pathway would inhibit growth and tumorigenicity of human thyroid cancer cell lines with mutations of RET or BRAF.
We first examined the effects of AAL-881 and LBT-613, two inhibitors of RAF kinase activity, on RAF-MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK activation in thyroid PCCL3 cells after conditional induction of expression of H-RAS(G12V) or BRAF(V600E). Both compounds blocked RAS and RAF-dependent MEK and ERK phosphorylation. They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations. Inhibition of ERK phosphorylation was transient in TPC1 and ARO cells, with recovery of ERK phosphorylation associated with concomitant down-regulation of the MAPK phosphatases MKP-3 and DUSP5. Both compounds inhibited growth of all cell lines, with LBT-613 being approximately 10-fold more potent than AAL-881. TPC1 cells were more sensitive to growth inhibition (IC50 0.1-0.25 and approximately 0.05 micromol/L for AAL-881 and LBT-613, respectively) than BRAF + lines (IC50 2.5-5 and 0.1-0.5 micromol/L, respectively). Growth inhibition was associated with G1 arrest, and induction of cell death. Growth of ARO and NPA tumor xenografts was inhibited by LBT-613 or AAL-881. MEK and ERK phosphorylation was inhibited by both compounds in ARO but not in NPA cell xenografts.
Compounds that inhibit kinase activity are effective growth inhibitors for poorly differentiated thyroid cancer cell lines with either RET or RAF mutations, and hold promise for treatment of most forms of papillary thyroid carcinoma.
AuthorsBin Ouyang, Jeffrey A Knauf, Eric P Smith, Lei Zhang, Tim Ramsey, Naeem Yusuff, David Batt, James A Fagin
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 12 Issue 6 Pg. 1785-93 (Mar 15 2006) ISSN: 1078-0432 [Print] United States
PMID16551863 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • AAL 881
  • Isoquinolines
  • LBT 613
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • raf Kinases
  • DUSP5 protein, human
  • DUSP6 protein, human
  • Dual Specificity Phosphatase 6
  • Dual-Specificity Phosphatases
  • Dusp6 protein, mouse
  • Protein Tyrosine Phosphatases
  • Animals
  • Blotting, Western
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Dual Specificity Phosphatase 6
  • Dual-Specificity Phosphatases
  • Enzyme Activation (drug effects)
  • Female
  • Humans
  • Isoquinolines (pharmacology)
  • Mice
  • Mice, Nude
  • Mutation (genetics)
  • Phosphorylation (drug effects)
  • Protein Kinase Inhibitors (pharmacology)
  • Protein Tyrosine Phosphatases (genetics, metabolism)
  • Proto-Oncogene Proteins B-raf (genetics, metabolism)
  • Proto-Oncogene Proteins c-ret (genetics, metabolism)
  • RNA, Messenger (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Thyroid Neoplasms (genetics, pathology, prevention & control)
  • Xenograft Model Antitumor Assays
  • raf Kinases (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: